证券代码：600135 证券简称：乐凯胶片 公告编号：2025-042 乐凯胶片股份有限公司 2025 年第二季度主要经营数据 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 乐凯胶片股份有限公司（以下简称"本公司"）根据《上海证券交易所上市公 司自律监管指引第 3 号——行业信息披露》第十三号附件的相关规定，将 2025 年第二季度主要经营数据公告如下： 一、2025 年第二季度主要产品经营情况 | 产品名称 | 单位 | 产量 | 销量 | 销售收入 （人民币万元） | | --- | --- | --- | --- | --- | | 银盐产品 | | | | | | 彩色相纸 | 万平米 | 1,356.02 | 1,330.28 | 14,784.89 | | 光伏产品 | | | | | | 太阳能电池背板 | 万平米 | 82.70 | 115.20 | 639.40 | | 医疗产品 | | | | | | 医用干式胶片 | 万平米 | 388.36 | 404.94 | 5,528.17 | | 光电产品 | | | | | | ...

Group 1 - The stock price of LeKai Film is reported at 8.20 yuan, down 1.91% from the previous trading day, with a trading range of 8.17 to 8.39 yuan and a transaction volume of 1.25 billion yuan [1] - LeKai Film's main business includes imaging materials, photovoltaic materials, and medical materials, with products such as color photographic paper and medical dry films [1] - The company is part of the plastic products industry and is involved in concepts related to Xiong'an New Area and the Beijing-Tianjin-Hebei region [1] Group 2 - The company will hold an extraordinary general meeting on August 13 to review amendments to the company's articles of association and the rules of procedure for general meetings [2] Group 3 - Data shows that LeKai Film experienced a net outflow of main funds amounting to 19.30 million yuan today, with a cumulative net outflow of 10.70 million yuan over the past five days [3]

Core Viewpoint - The photomaterial industry in China is experiencing significant growth driven by advancements in digitalization and intelligent technologies, with market size projected to increase from 25.12 billion yuan in 2019 to 34.32 billion yuan by 2024 [1][12]. Group 1: Industry Overview - Photomaterials are semiconductor materials with light-sensitive properties, categorized into silver salt and non-silver salt photomaterials, with applications in photography, printing, electronics, and medical fields [3][5]. - The industry has transitioned from traditional film to digital formats, facing challenges and opportunities due to the rise of digital photography and mobile imaging technologies [5][10]. Group 2: Industry Chain - The photomaterial industry consists of an upstream segment focused on light-sensitive substances and additives, a midstream segment for production, and a downstream segment for applications in various fields such as photography, film, medical diagnostics, and semiconductors [8]. Group 3: Market Dynamics - The demand for photomaterials has declined in traditional photography sectors but has increased in semiconductor and industrial applications, particularly in photoresist manufacturing [10]. - The Chinese photomaterial market is projected to reach 11.44 billion yuan by 2024, with a year-on-year growth of 4.8% [10]. Group 4: Competitive Landscape - The market has shifted from being dominated by a few large companies like Kodak and Fujifilm to a more competitive landscape with both foreign and domestic companies, including major players like LeKai Film and Shenzhen Rongda Photomaterials [14][15]. Group 5: Industry Trends - The photomaterial industry has a broad development outlook, with increasing demand in high-end markets such as medical imaging and 3D printing [19]. - Environmental pressures are rising, necessitating advancements in eco-friendly production processes and waste management [20]. - Intense market competition, particularly in the low-end segment, is leading to price wars and potential compromises in product quality [21][22].

Core Viewpoint - The company is facing significant challenges in its photovoltaic business, with a notable decline in revenue and profitability, particularly in solar cell backsheet products, which have seen a drastic drop in sales and margins due to increased market competition and price reductions [1][2][3]. Financial Performance - For the fiscal year 2024, the company reported a revenue of 1.485 billion yuan, a nearly 30% decrease year-on-year, and a net loss attributable to shareholders of 62 million yuan, marking two consecutive years of losses [1][2]. - The revenue from solar cell backsheet products plummeted by 76%, with a gross margin dropping by 20 percentage points to -18.13% [1][2]. Inventory and Impairment - As of June 30, 2025, the company identified further impairment signs in its photovoltaic-related inventory, estimating a potential impairment amount not exceeding 3 million yuan, which will be disclosed in the 2025 semi-annual report [1][5]. - The ending inventory balance stood at 308 million yuan, with the provision for inventory impairment increasing from 5.18% at the beginning of the period to 5.58% at the end [1][5]. Market Trends and Competitive Landscape - The solar photovoltaic industry is experiencing a significant downturn, with a 40% drop in component bidding prices and a 33.9% decrease in export value for photovoltaic products [2][3]. - The market for solar cell backsheet products is shrinking, with the share of single-glass components using these products dropping from 60% to 15% [2][3]. Customer and Revenue Analysis - The company’s main customers in the photovoltaic sector have also reported significant declines in revenue and profits, impacting the company's sales [3][4]. - The company operates on a direct transaction model with photovoltaic module manufacturers, which has been adversely affected by the overall market conditions [3][4]. Cost Structure and Pricing - The cost structure for solar cell backsheet products shows that over 70% of costs are attributed to materials, with transportation costs increasing due to geographical factors, adding approximately 0.4 yuan per square meter compared to competitors [5][6]. - The average selling price of solar cell backsheet products has decreased by 20% year-on-year, further squeezing margins [5][6]. Strategic Adjustments - In response to the challenging market environment, the company is optimizing its product structure by ceasing production of unprofitable solar cell backsheet products and actively developing new products [5][6]. - The company is also expanding into new business areas, including high-performance separation membranes, aligning with national carbon neutrality goals [6][7].

证券代码：600135 证券简称：乐凯胶片 公告编号：2025-020 2025 年第一季度主要经营数据 本公司及董事会全体成员保证公告内容的真实、准确和完整，对公告的虚 假记载、误导性陈述或者重大遗漏负连带责任。 乐凯胶片股份有限公司（以下简称"本公司"）根据《上海证券交易所上市公 司自律监管指引第 3 号——行业信息披露》第十三号附件的相关规定，将 2025 年第一季度主要经营数据公告如下： 一、2025 年第一季度主要产品经营情况 | 银盐产品 | | | | --- | --- | --- | | 硝酸银 | 31.23% | 10.71% | | 纸基 | -5.96% | -3.09% | | 光伏产品 | | | | F 膜 | -13.35% | -12.49% | | 医疗产品 | | | | 聚酯切片 | -9.05% | -6.67% | | 光电产品 | | | | 二氯甲烷 | 8.15% | -0.40% | 乐凯胶片股份有限公司 | 产品名称 | 单位 | 产量 | 销量 | 销售收入 （人民币万元） | | --- | --- | --- | --- | --- | | 银盐产 ...

Company Performance - As of March 28, the stock price of Giant Star Medical Holdings (02393.HK) closed at HKD 0.108, up 8.0% with a trading volume of 2.0375 million shares and a turnover of HKD 21.22 million, showing a volatility of 8.0% [1] - Over the past month, Giant Star Medical Holdings has seen a cumulative increase of 42.86%, and a year-to-date increase of 61.29%, outperforming the Hang Seng Index by 17.54% [1] - For the fiscal year ending June 30, 2024, the company reported total revenue of CNY 1.274 billion, a year-on-year decrease of 13.51%, while net profit attributable to shareholders was CNY 1.089 billion, a significant increase of 30,014.43% [1] Industry Valuation - Currently, there are no institutional investment ratings for Giant Star Medical Holdings [2] - The average price-to-earnings (P/E) ratio for the healthcare equipment and services industry is -3.55 times, with a median of 4.98 times. Giant Star Medical Holdings has a P/E ratio of 0.2 times, ranking first in the industry [2] - Other companies in the industry include Jingjiu Kangliao (00648.HK) with a P/E ratio of 0.38 times, Global Medical (02666.HK) at 4.54 times, Yongsheng Medical (01612.HK) at 4.58 times, Ruici Medical (01526.HK) at 5.38 times, and New Century Medical (01518.HK) at 6.16 times [2] Company Overview - Giant Star Medical Holdings is recognized as one of China's leading high-margin medical consumables and equipment companies, focusing on high-margin medical consumables and equipment, specifically medical imaging products and in vitro diagnostic products [3] - The company has established a broad sales network in China and has gained the trust of international manufacturers such as Fujifilm, Roche Diagnostics, Becton Dickinson, and Thermo Fisher Scientific [3] - Giant Star Medical is the exclusive manufacturer of medical film for Fujifilm in China and one of the largest distributors of Roche's in vitro diagnostic products in the country [3] - The company aims to continue seeking potential acquisition opportunities and establish strategic partnerships with industry giants to strengthen its position in the medical industry [3]

证券代码：600135 证券简称：乐凯胶片 公告编号：2025-011 乐凯胶片股份有限公司（以下简称"本公司"）根据《上海证券交易所上市公 司自律监管指引第 3 号——行业信息披露》第十三号附件的相关规定，将 2024 年第四季度主要经营数据公告如下： 一、2024 年第四季度主要产品经营情况 | 产品名称 | 单位 | 产量 | 销量 | 销售收入 （人民币万元） | | --- | --- | --- | --- | --- | | 银盐产品 | | | | | | 彩色相纸 | 万平米 | 1,184.99 | 1,273.39 | 14,249.50 | | 光伏产品 | | | | | | 太阳能背板 | 万平米 | 207.78 | 309.91 | 1,418.56 | | 医疗产品 | | | | | | 医用干式胶片 | 万平米 | 519.65 | 545.41 | 8,571.89 | | 光电产品 | | | | | | 膜 TAC | 万平米 | 420.56 | 408.39 | 5,405.38 | 乐凯胶片股份有限公司 2024 年第四季度主要经营数据 本公司及董事会全体成员 ...